Contact Us

special ASH update

TEXT SIZE

print share |

12.17.06   An Overview of ASH 2006
	The IMF went to ASH and asked several key participants for their views of this important meeting. The overviews are in English, Turkish, Czech, Spanish, French, and German.

---

12.23.07   Overview of ASH 2006 in Czech
	Prof. Roman Hájek Masaryk University Brno, Czech Republic

---

12.17.07   Ein Überblick über den ASH-Kongress
	Hartmut Goldschmidt, MD Universitätsklinikum Heidelberg (University Clinic of Heidelberg) und Nationales Centrum für Tumorerkrankungen (and the National Center of Tumor Diseases) Heidelberg, Deutschland

---

12.17.07   Overview of ASH 2006 in Hebrew
	Dina Ben-Yehuda, MD Hadassah University Hospital Jerusalem, Israel

---

12.17.06   A Randomized Study of Lenalidomide with High- or Low-Dose Dexamethasone in the Treatment of Newly Diagnosed Myeloma
	S. Vincent Rajkumar, MD Mayo Clinic Rochester, MN

---

12.17.06   An International Randomized Trial of Thal/Dex vs Dexamethasone Alone
	S. Vincent Rajkumar, MD Mayo Clinic Rochester, MN

---

12.17.06   An Overview of Planned Randomized Clinical Trials for Newly Diagnosed Younger and Older Patients in Spain
	Jesús San Miguel, MD Hospital Clinico Universitario Universidad de Salamanca Salamanca, Spain

---

12.17.06   Analysis of Phase III Study of Revlimid + Dexamethasone in Patients >65 Years
	Asher A. Chanan-Khan, MD Roswell Park Cancer Institute Buffalo, NY

---

12.17.06   Breaking the Plateau Response in MM: Results of a Pilot Study of Vel/Dex/Doxil (DoVeD)
	Ruben Niesvizky, MD New Presbyterian Hospital Weill Cornell Medical Center New York, NY

---

12.17.06   Identification of Mutations in the NFkB Pathway That Predict Velcade Response
	A. Keith Stewart, MD Mayo Clinic Scottsdale, AZ

---

12.17.06   Long Term Results of a Study of Rev/Dex in Newly Diagnosed Patients
	Martha Q. Lacy, MD Mayo Clinic Rochester, MN

---

12.17.06   Long-Term Follow-Up of a Phase II Trial of Vel/Dex in Frontline Therapy for Myeloma
	Sundar Jagannath, MD St. Vincent’s Comprehensive Cancer Center New York, NY

---

12.17.06   Phase I/II Study of Revlimid + Melphalan/Prednisone (R-MP) for Newly Diagnosed Myeloma
	Antonio Palumbo, MD Ospedale Molinette Torino, Italy

---

12.17.06   Relationship Between Quality of Response to Velcade and Clinical Benefit
	Ruben Niesvizky, MD New Presbyterian Hospital Weill Cornell Medical Center New York, NY

---

12.17.06   Revlimid-Induced Myelosuppression is Potentially Associated with Renal Dysfunction in Treatment-Naïve MM Patients Receiving BiRD
	Ruben Niesvizky, MD New Presbyterian Hospital Weill Cornell Medical Center New York, NY

---

12.17.06   The Use of Lenalidomide +/- Dexamethasone in Patients with AL Amyloidosis
	Angela Dispenzieri, MD Mayo Clinic Rochester, MN

---

12.17.06   The Use of Velcade + Melphalan/Prednisone in Elderly Non-Transplant Patients
	Jesús San Miguel, MD Hospital Clinico Universitario Universidad de Salamanca Salamanca, Spain

---

12.17.06   The Use of Velcade as First-Line Therapy in High-Risk Myeloma
	Angela Dispenzieri, MD Mayo Clinic Rochester, MN

---

12.17.06   Use of Revlimid With or Without Steroids in Relapsed/Refractory Myeloma Patients with Elevated Baseline Serum Creatinine
	Donna E. Reece, MD Princess Margaret Hospital Toronto, Canada

---

12.17.06   Velcade and Doxil as Induction Therapy for Newly Diagnosed Myeloma
	Robert Z. Orlowski, MD Lineberger Cancer Center University of North Carolina Chapel Hill, NC

---

12.17.06   A Phase I/II Study of Revlimid, Adriamycin, and Dexamethasone (RAD) in Patients with Relapsed/Refractory Myeloma
	Stefan Knop, MD Universitätsklinikums Würzburg (University Clinic of Wuerzburg) Würzburg, Germany

---

12.17.06   A Phase II Study of Velcade, Doxil, and Thalidomide (VDT) in Relapsed/Refractory Myeloma
	Asher A. Chanan-Khan, MD Roswell Park Cancer Institute Buffalo, NY

---

12.17.06   A Subset Study of Lenalidomide/Dexamethasone vd Dexamethasone Alone After Thalidomide Therapy in Relapsed/Refractory Myeloma
	Michael Wang, MD MD Anderson Cancer Center Houston, Texas USA

---

12.17.06   Amplification of 1q21 Is Associated with Poor Outcome after Treatment with Bortezomib in Relapsed/Refractory Multiple Myeloma
	Heinz Ludwig, MD Wilhelminenspital der Stadt Wein Vienna, Austria

---

12.17.06   Combination of Revlimid and Velcade in the Treatment of Relapsed/Refractory Myeloma
	Paul G. Richardson, MD Dana Farber Cancer Institute Boston, Massachusetts USA

---

12.17.06   Phase I Study of BB-10901 (huN901-DM1) in Patients with Relapsed/Refractory CD56-Positive Myeloma
	Asher A. Chanan-Khan, MD Roswell Park Cancer Institute Buffalo, NY

---

12.17.06   Phase I/II Study of a Combination of Velcade, Melphalan, Prednisone, and Thalidomide (VMPT) for Relapsed Myeloma
	Antonio Palumbo, MD Ospedale Molinette Torino, Italy

---

12.17.06   Phase I/II Study of Oral Cyclophosphamide, Prednisone, and Velcade in Patients with Relapsed/Refractory Myeloma
	Donna E. Reece, MD Princess Margaret Hospital Toronto, Canada

---

12.17.06   Phase III International Randomized Study of Velcade vs Velcade/Doxil in Relapsed/Refractory Myeloma
	Robert Z. Orlowski, MD Lineberger Cancer Center University of North Carolina Chapel Hill, NC

---

12.17.06   Revlimid in Combination with Dex is More Effective than Dexamethasone Alone at First Relapse
	Edward A. Stadtmauer, MD Hospital of the University of Pennsylvania Philadelphia, PA

---

12.17.06   A Phase I Study of HCD122 (formerly CHIR1212), a Monoclonal Antibody to CD40, in Relapsed/Refractory Myeloma
	William Bensinger, MD University of Washington Fred Hutchinson Cancer Research Center Seattle, WA

---

12.17.06   A Retrospective Study of the Significance of Complete Response (CR) on Outcomes in Myeloma Treatment
	Michael Wang, MD MD Anderson Cancer Center Houston, Texas USA

---

12.17.06   Mi-63, a Small Molecule Inhibitor of MDM2-p53 Interaction, Has Significant In Vitro Activity in Multiple Myeloma
	Shaji Kumar, MD Mayo Clinic Rochester, MN

---

12.17.06   New Proteasome Inhibitor NPI-0052
	Michael Palladino, PhD Nereus Pharmaceuticals San Diego, CA

---

12.17.06   Phase I Study of KOS-953 + Velcade in Patients with Relapsed/Refractory MM
	Paul G. Richardson, MD Dana Farber Cancer Institute Boston, Massachusetts USA

---

12.17.06   SNP Association with Event-Free Survival (EFS) in Myeloma from Two Phase III Trials Using the Bank On A Cure SNP Chip
	Brian Van Ness, PhD University of Minnesota Institute of Human Genetics Minneapolis, MN

---

12.17.06   The Effect of Genetically Modified Measles Virus on Myeloma Cells in Vitro
	Hermann Einsele, MD Universitätsklinikums Würzburg (University Clinic of Wuerzburg) Würzburg, Germany

---

12.17.06   The Genetic Contribution to the Etiology of Thalidomide-Associated VTE
	Gareth Morgan, MD The Royal Marsden Hospital Sutton, Surrey, UK

---

12.17.06   A Phase I/II Study of Consolidation Therapy with Velcade after Tandem Transplant
	Hermann Einsele, MD Universitätsklinikums Würzburg (University Clinic of Wuerzburg) Würzburg, Germany

---

12.17.06   A Phase II Study of Alternating Velcade and Dexamethasone as Induction Therapy Prior to Transplant in Newly Diagnosed Patients
	Jesús San Miguel, MD Hospital Clinico Universitario Universidad de Salamanca Salamanca, Spain

---

12.17.06   A Retrospective Analysis of High Dose Therapy in Patients with Renal Insufficiency
	Shaji Kumar, MD Mayo Clinic Rochester, MN

---

12.17.06   A Retrospective Analysis of the Significance of Measurable Disease at Time of Transplant
	Shaji Kumar, MD Mayo Clinic Rochester, MN

---

12.17.06   A Retrospective Analysis of Three Induction Regimens for Newly Diagnosed Myeloma Prior to Transplant
	Shaji Kumar, MD Mayo Clinic Rochester, MN

---

12.17.06   A Retrospective Study of the Significance of VGPR/CR in the IFM 99 Trials
	Jean-Luc Harousseau, MD Hematologie Clinique CHU Hotel Dieu Nantes, France

---

12.17.06   An Analysis of Response Criteria Post-Stem Cell Transplant in AL Amyloidosis
	Morie Gertz, MD Mayo Clinic Rochester, MN

---

12.17.06   An Interim Analysis of Velcade/Dexamethasone vs VAD as Induction Therapy Prior to Transplant in Newly Diagnosed Myeloma
	Jean-Luc Harousseau, MD Hematologie Clinique CHU Hotel Dieu Nantes, France

---

12.17.06   Prospective Randomized Comparison of Double Transplant with Melphalan 200 vs Triple Transplant with Melphalan 100
	Heinz Ludwig, MD Wilhelminenspital der Stadt Wein Vienna, Austria

---

12.17.06   Velcade Added to High-Dose Cytoxan and GCSF as a Mobilization Regimen for Stem Cell Collection Prior to HDT
	Ruben Niesvizky, MD New Presbyterian Hospital Weill Cornell Medical Center New York, NY

---